Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.005 per share
-
Shares outstanding
-
110M
-
Number of holders
-
19
-
Total 13F shares, excl. options
-
331K
-
Shares change
-
-1.82K
-
Total reported value, excl. options
-
$728K
-
Value change
-
-$4.86K
-
Number of buys
-
5
-
Number of sells
-
-7
-
Price
-
$2.18
Significant Holders of Ernexa Therapeutics Inc. - Common Stock, par value $0.005 per share (ERNA) as of Q3 2023
21 filings reported holding ERNA - Ernexa Therapeutics Inc. - Common Stock, par value $0.005 per share as of Q3 2023.
Ernexa Therapeutics Inc. - Common Stock, par value $0.005 per share (ERNA) has 19 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 331K shares
of 110M outstanding shares and own 0.3% of the company stock.
Largest 10 shareholders include Cypress Point Wealth Management, LLC (94.4K shares), Naviter Wealth, LLC (79.3K shares), Corient Private Wealth LLC (51.3K shares), Sippican Capital Advisors (28.1K shares), VANGUARD GROUP INC (24.9K shares), GEODE CAPITAL MANAGEMENT, LLC (22.5K shares), BlackRock Inc. (16.6K shares), BALDWIN BROTHERS LLC/MA (9.47K shares), Tower Research Capital LLC (TRC) (4.6K shares), and UBS Group AG (105 shares).
This table shows the top 19 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.